HOME > BUSINESS > Mylan and Biocon submits breast cancer drug application to USFDA

Mylan and Biocon submits breast cancer drug application to USFDA

canMylan N.V. and Biocon Ltd. said they submitted Mylan’s biologics license application for a proposed biosimilar Trastuzumab, to the U.S. Food and Drug Administration.

Biosimilar trastuzumab is a proposed biosimilar to branded Trastuzumab, which is indicated to treat certain HER2-positive breast and gastric cancers.

HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.

Mylan and Biocon said that this has the potential to be the first submission of a proposed biosimilar trastuzumab in the U.S.

Mylan President Rajiv Malik said, “The FDA submission for biosimilar trastuzumab marks Mylan’s first FDA biosimilar submission from our broad portfolio of biosimilar products in development and our product has the opportunity to be the first biosimilar trastuzumab approved in the U.S.”

“Our trastuzumab biosimilar is already being sold in 11 developing markets, including India, and we look forward to bringing the product to market in the U.S. and Europe upon approval.”

The submitted license application includes a package of analytical similarity, nonclinical and clinical data. The clinical data consists of two pharmacokinetic studies and the heritage confirmatory efficacy and safety trial.

The results of the heritage trial were presented at this year’s American Society of Clinical Oncology (ASCO) annual Meeting and the European Society for Medical Oncology (ESMO) Congress.

Dr Arun Chandavarkar, CEO & Joint MD, Biocon, said, “Cancer patients in India and emerging markets have benefited with our trastuzumab and this advancement in the U.S. will enable us to enhance access to this affordable therapy to larger patient pools.”

Mylan and Biocon are partners on a portfolio of biosimilar and insulin products. The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace.

Mylan has commercialization rights for the proposed biosimilar trastuzumab in the U.S., Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries.

Biocon has co-commercialization rights with Mylan for the product in the rest of the world.

Mylan is a global pharmaceutical company which offers a more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS worldwide depend.

It has markets in more than 165 countries and territories with 40,000 employees.

Biocon Limited is India’s largest and fully-integrated biopharmaceutical company.

Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAbTM (Trastuzumab), BIOMAb-EGFRTM (Nimotuzumab) and ALZUMAbTM (Itolizumab), an anti-CD6 monoclonal antibody.

Follow ULTRA.news
Smuggling down on Indo-Bangladesh border, up on Bhutanese side Incidents related to smuggling of fertilizer and narcotics on the Indo-Bangladesh border fell sharply in 2016, but there was a compensatory increase in drug smuggling cases along India's border with Bhutan and Nepal, according to data from the Union Home Ministry.Fertilizers ...
Lopinavir syrup for children with HIV now available across India – Govt NACO ran out of Lopinavir stock in FebruaryMinister of health and family welfare Anupriya Patel said Lopinavir syrup, the life-saving drug given to infants and toddlers with HIV has been restocked by the National Aids Control Organization."NACO has done an emergency proc...
Cancer cases in India jump 4.5% in 2016 to 14.5 lakh The number of cancer cases in India jumped by 4.5% in 2016 to 14.51 lakh, according to the Indian Council of Medical Research or ICMR.The number implies that 1 in 930 people in India have cancer as of 2016.In 2015, the total number of cancer patients in India was estima...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta ta...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharm...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in t...
Almebic Pharmaceuticals receives inspection report from USFDA Alembic Pharmaceuticals Ltd., said it received an Establishment Inspection Report from the United States Food and Drug Administration for the inspection carried out at their formulation facility at Panelav, Gujarat.The FDA has the authority to inspect any establishment in whi...
Shilpa Medicare receives USFDA approval for generic bone marrow drug Shilpa Medicare Ltd said it received an approval from the United states Food & Drug Administration for Azacitidine injection.Azacitidine is used to treat myelodysplastic syndrome - a group of conditions in which the bone marrow produces blood cells that are misshapen and ...
Lupin receives FDA approval for generic Namenda XR dementia capsules Pharma Major Lupin Ltd said it received final approval from United States Food and Drug Administration for selling Memantine Hydrochloride extended-release capsules, a generic version of Allergan’s Namenda XR capsules.Namenda XR extended-release capsules are approved by the...
Aurobindo Pharma to launch HIV drug in Africa this year, gets tentative FDA nod Aurobindo Pharma Limited, a pharmaceutical manufacturing company based in Hyderabad, said it received a tentative approval for HIV drug Dolutegravir from US Food & Drug Administration.It is the first FDA approval of a generic version of Dolutegravir. Through a tie up w...
Sharon Bio Medicines receives FDA approval for Tajola API plant Indian Pharmaceutical company Sharon bio medicine Ltd said it received the Establishment Inspection Report (EIR) from United States Food and Drug Amnistration for its manufacturing plant located at Tajola in Raigad Dist., Maharashtra.The plant, which will make Active Pharmace...
Dr Reddy’s Laboratories launches Paricalcitol injection in the US Market Dr. Reddy's Laboratories Ltd said it launched Paricalcitol Injection, a therapeutic equivalent generic version of Zemplar injection in the United States market approved by the US Food & Drug Administration (USFDA).The Zemplar brand and generic had US sales of approximatel...
Lupin receives tentative approval for generic Avelox tablets Pharma Major Lupin Limited announced that its US subsidiary, Gavis Pharmaceuticals received a tentative approval from the US FDA for selling Moxifloxacin hydrochloride tablets, a generic version of Bayer Healthcare Pharmaceuticals' Avelox tablets.Lupin’s Moxifloxacin hydr...
Dr. Reddy’s Laboratories launches heart drug in the US Pharma company Dr. Reddy's Laboratories Ltd said it launched Nitroglycerin sublingual tablets -- a therapeutic equivalent generic version of Nitrostat sublingual tablets -- in the US market.The medication is used before physical activities (such as exercise, sexual activity) ...
US FDA updates warning against widespread use of fluoroquinolones The US Food & Drug Administration issued a warning against casual usage of fluoroquinolone antibiotics, arguably the most widely used broad-spectrum antibiotic in India.USFDA advised that the side effects caused by the use of fluoroquinolone antibacterial drugs would outw...
Lupin receives tentative US FDA approval for generic version of Paxil Indian pharma major Lupin Ltd announced today that it received tentative approval from the United States Food & Drug Administration to market a generic version of Apotex Technology's 'Paxil' Paroxetine tablets.The medicine is indicated for the treatment of major depressiv...
EMA accepts review for Mylan and biocon’s trastuzumab biosimilar Mylan N.V. and Biocon Ltd. said the European Medicines Agency accepted for review Mylan’s Marketing Authorization Application for a proposed biosimilar version of biosimilar Trastuzumab, a medicine used to treat breast and gastric cancers.This is the second biosimilar submis...
Stride Shasun receives USFDA approval for constipation treatment Pharma company Strides Shasun announced that it received the United States Food & Drug Administration (USFDA) approval for Polyethylene Glycol powder to treat occasional constipation.The powder when consumed as a solution works by softening the stool and increasing the fr...
USFDA issues establishment inspection report for NATCO Pharma’s Chennai plant NATCO pharma, a Hyderabad based pharmaceutical company, said it received establishment inspection report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted during the period February 8 – February 12 at its Chemical Division in Chennai.Earlier ...
Stride Shasun receives USFDA Approval for Ranitidine Tablets Pharma company Strides Shasun announced that it received the United States Food & Drug Administration (USFDA) approval for generic Ranitidine Tablets, used to treat and prevent ulcers in the stomach and intestines.Ranitidine tablet is the first integrated product approval...
Lupin’s potassium deficiency drug gets FDA approval Lupin Ltd announced today that its US subsidiary, Gavis Pharmaceuticals LLC, has received final approval for its Potassium Chloride Extended-Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA).The capsule is for t...
Biocon’s European approval for cholesterol drug opens $1.2 billion market Biocon Ltd said it has received European approvals for generic versions of AstraZeneca's cholesterol drug Crestor, opening up a billion dollar market.The approval has been obtained for Rosuvastatin Calcium 5 mg, 10 mg, 20 mg and 40 mg tablets, indicated for hyperlipidemia...
Biocon unit Syngene Intl gets FIPB approval for IPO Syngene International, an India-based Contract Research Organisation and a subsidiary of Biocon Ltd, announced that it has received the Foreign Investment Promotion Board (“FIPB”) approval for raising the foreign investment to 44% from the earlier approved 10% by way of its I...
Glenmark announces discovery of novel cancer drug Glenmark Pharmaceuticals has announced the discovery of a new anti-cancer therapy by its Swiss subsidiary.The new drug, GBR 1302, will target breast cancer and ovarian cancer, and the company expects to start clinical studies this year.Unlike normal drugs, the new dru...